CytomX Therapeutics Inc
CTMX3.570USD
+0.240+7.21%
收盤 10/31, 16:00（美東）報價延遲15分鐘
588.73M總市值
12.27本益比TTM
關於 CytomX Therapeutics Inc 公司
CytomX Therapeutics, Inc. 是一家臨牀階段、專注於腫瘤學的生物製藥公司，致力於開發旨在定位於腫瘤微環境的新型條件激活生物製劑。該公司正在利用其 PROBODY 治療技術平臺推進潛在的同類首創和同類最佳抗體療法。其產品線包括多種治療方式的治療候選藥物，包括抗體-藥物偶聯物 (ADC)、T 細胞接合劑和免疫調節劑（如細胞因子）。其臨牀階段產品線包括 CX-904、CX-2051 和 CX-801。CX-904 是一種條件激活的 T 細胞接合抗體，靶向腫瘤細胞上的表皮生長因子受體和 T 細胞上的 CD3 受體，並與安進公司建立了全球聯合開發聯盟。 CX-2051 是一種針對上皮細胞粘附分子 (EpCAM) 的條件激活 ADC，具有適用於多種表達 EpCAM 的上皮癌的潛在適用性。
CytomX Therapeutics Inc簡介
公司代碼CTMX
公司名稱CytomX Therapeutics Inc
上市日期Oct 08, 2015
CEODr. Sean A. Mccarthy, Ph.D.
員工數量119
證券類型Ordinary Share
年結日Oct 08
公司地址151 Oyster Point Blvd.
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編94080
電話16505153185
網址https://cytomx.com/
公司代碼CTMX
上市日期Oct 08, 2015
CEODr. Sean A. Mccarthy, Ph.D.
CytomX Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Elaine V. Jones, Ph.D.
Dr. Elaine V. Jones, Ph.D.
Independent Director
Independent Director
5.14K
--
Dr. Yu-Waye (Wayne) Chu, M.D.
Dr. Yu-Waye (Wayne) Chu, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
4.72K
-96.52%
Mr. Chris Ogden
Mr. Chris Ogden
Senior Vice President, Chief Financial Officer, Assistant Secretary
Senior Vice President, Chief Financial Officer, Assistant Secretary
--
--
Ms. Halley Gilbert
Ms. Halley Gilbert
Independent Director
Independent Director
--
--
Dr. Zhen Su, M.D.
Dr. Zhen Su, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew P. (Matt) Young
Mr. Matthew P. (Matt) Young
Lead Independent Director
Lead Independent Director
--
--
Dr. Mani Mohindru, Ph.D.
Dr. Mani Mohindru, Ph.D.
Independent Director
Independent Director
--
--
Dr. Alan Ashworth, Ph.D.
Dr. Alan Ashworth, Ph.D.
Independent Director
Independent Director
--
--
Mr. James Robert (Jim) Meyers
Mr. James Robert (Jim) Meyers
Independent Director
Independent Director
--
--
Dr. Sean A. Mccarthy, Ph.D.
Dr. Sean A. Mccarthy, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Elaine V. Jones, Ph.D.
Dr. Elaine V. Jones, Ph.D.
Independent Director
Independent Director
5.14K
--
Dr. Yu-Waye (Wayne) Chu, M.D.
Dr. Yu-Waye (Wayne) Chu, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
4.72K
-96.52%
Mr. Chris Ogden
Mr. Chris Ogden
Senior Vice President, Chief Financial Officer, Assistant Secretary
Senior Vice President, Chief Financial Officer, Assistant Secretary
--
--
Ms. Halley Gilbert
Ms. Halley Gilbert
Independent Director
Independent Director
--
--
Dr. Zhen Su, M.D.
Dr. Zhen Su, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew P. (Matt) Young
Mr. Matthew P. (Matt) Young
Lead Independent Director
Lead Independent Director
--
--
收入明細
FY2025Q1
FY2024
FY2024Q3
FY2023
FY2022
FY2021
FY2020
FY2019
暫無數據
地區USD
名稱
營收
佔比
United States
50.92M
0.00%
業務
地區
暫無數據
股東統計
更新時間: 8月23日 週六
更新時間: 8月23日 週六
持股股東
股東類型
持股股東
持股股東
佔比
VR Adviser, LLC
8.47%
Longitude Capital Management Co., LLC
7.00%
Tang Capital Management, LLC
6.71%
Perceptive Advisors LLC
5.87%
The Vanguard Group, Inc.
5.69%
其他
66.26%
持股股東
持股股東
佔比
VR Adviser, LLC
8.47%
Longitude Capital Management Co., LLC
7.00%
Tang Capital Management, LLC
6.71%
Perceptive Advisors LLC
5.87%
The Vanguard Group, Inc.
5.69%
其他
66.26%
股東類型
持股股東
佔比
Hedge Fund
31.85%
Venture Capital
20.65%
Investment Advisor
15.41%
Investment Advisor/Hedge Fund
11.30%
Private Equity
11.00%
Individual Investor
0.64%
Research Firm
0.24%
Corporation
0.23%
Pension Fund
0.14%
其他
8.53%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
190
149.41M
90.60%
+52.66M
2025Q2
174
79.06M
50.13%
+5.55M
2025Q1
180
46.88M
32.26%
-27.51M
2024Q4
187
47.68M
60.93%
-26.52M
2024Q3
193
52.18M
66.81%
-19.54M
2024Q2
203
57.59M
74.04%
-4.03M
2024Q1
239
45.58M
66.89%
-10.30M
2023Q4
245
33.58M
50.13%
-26.30M
2023Q3
276
33.60M
50.33%
-37.55M
2023Q2
290
35.13M
52.97%
-38.77M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
VR Adviser, LLC
13.97M
8.47%
+977.38K
+7.52%
Jun 30, 2025
Longitude Capital Management Co., LLC
11.54M
7%
+11.54M
--
May 13, 2025
Tang Capital Management, LLC
11.07M
6.71%
+4.35M
+64.72%
Jun 30, 2025
Perceptive Advisors LLC
9.68M
5.87%
+2.69M
+38.41%
Aug 14, 2025
The Vanguard Group, Inc.
9.38M
5.69%
+4.26M
+83.29%
Jun 30, 2025
Fidelity Management & Research Company LLC
8.66M
5.25%
+8.55M
+7898.03%
Jun 30, 2025
OrbiMed Advisors, LLC
8.46M
5.13%
+8.46M
--
Jun 30, 2025
Point72 Asset Management, L.P.
8.08M
4.9%
-5.01M
-38.26%
Jun 30, 2025
Commodore Capital LP
7.69M
4.66%
+7.69M
--
Jun 30, 2025
Franklin Advisers, Inc.
5.77M
3.5%
+5.77M
--
Jun 30, 2025
查看更多
持股ETF
更新時間: 20 小時前
更新時間: 20 小時前
機構名稱
佔比
Formidable ETF
2.19%
Inspire Fidelis Multi Factor ETF
1.65%
Invesco NASDAQ Future Gen 200 ETF
0.76%
First Trust Dow Jones Select MicroCap Index Fund
0.64%
Fidelity Enhanced Small Cap ETF
0%
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
Dimensional US Core Equity 1 ETF
0%
Formidable ETF
佔比2.19%
Inspire Fidelis Multi Factor ETF
佔比1.65%
Invesco NASDAQ Future Gen 200 ETF
佔比0.76%
First Trust Dow Jones Select MicroCap Index Fund
佔比0.64%
Fidelity Enhanced Small Cap ETF
佔比0%
iShares Micro-Cap ETF
佔比0%
iShares Core S&P Total U.S. Stock Market ETF
佔比0%
DFA Dimensional US Core Equity Market ETF
佔比0%
Dimensional US Core Equity 1 ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
